Home / Market News / $CRL
benzinga Corporate Catalyst Impact 55/100 ● positive

Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

Oct 13, 2026, 4:25 PM UTC · Primary ticker $CRL

Morgan Stanley analyst Ricky Goldwasser has reiterated an Overweight rating on Charles River Laboratories and increased its price target from $300 to $340. This indicates a positive outlook from a prominent financial institution, suggesting potential upside for the stock.

Morgan Stanley analyst Ricky Goldwasser raised the price target for Charles River Laboratories (CRL) from $300 to $340 while maintaining an Overweight rating. This action signals increased confidence from a major investment bank in CRL's future performance. For traders, this could be a short-term positive catalyst, potentially leading to increased buying interest and upward price movement. The long-term implication is a reinforced positive sentiment around the company's fundamentals, though actual stock performance will depend on broader market conditions and CRL's execution. The key opportunity for traders is to capitalize on the potential upward momentum following this analyst upgrade.

$CRL positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.